FDA approved SPRAVATO® (esketamine) in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
On Jan. 21, 2025, Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of a…
Risk of depression and heart disease linked in women
On Dec. 5, 2024, researchers Dr Sonia Shah and Dr Clara Jiang from the University of Queensland’s Institute…
AARP and Leading Research Organizations Announced Risk Factors of Dementia Research Findings
On Nov. 15, 2024, the AARP, the Alzheimer’s Disease Data Initiative (AD Data Initiative), and the Institute for…
Otsuka and Click Therapeutics announce FDA clearance of Rejoyn, first prescription digital therapeutic for MDD
On Apr. 1, 2024, Otsuka Pharmaceutica and Click Therapeutics announced that the U.S. Food and Drug Administration (FDA)…
ZURZUVAE (zuranolone) CIV, a landmark treatment for women with postpartum Depression, available in the U.S.
On Dec. 14, 2023, Biogen and Sage Therapeutics announced ZURZUVAE (zuranolone) 50 mg (two 25 mg capsules per…
U.S. FDA approved ZURZUVAE (zuranolone), the First and only oral treatment for Women with postpartum depression
On Aug. 4, 2023, Biogen and Sage Therapeutics announced that the U.S. Food and Drug Administration (FDA) had…
Amphastar Pharmaceuticals received FDA approval for Naloxone hydrochloride nasal spray
On Mar. 8, 2023, Amphastar Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had granted approval…
COVID-19 | Diagnostics | NIH | Therapeutics
Depression, loneliness associated with increased hospitalization risk after COVID-19
On May 19, 2022, the U.S. National Institutes of Health (NIH) announced that people who reported in a…
NIH researchers linked depression during pregnancy to placental gene modifications
On Oct. 6, 2021, a study by researchers at the National Institutes of Health (NIH) found that episodes…
XPhyto added mescaline production to psychedelic medicine programs
On Feb. 10, 2021, XPhyto announced it had added mescaline production to its psychedelic medicine programs. Further to…
Postpartum depression may persist three years after giving birth
On Oct. 27, 2020, a National Institutes of Health (NIH) study of 5,000 women found that approximately 1…
Biotechnology | Diagnostics | Neurology | NIH
NIH study showed markers in blood can help identify risk for complications after Brain Injury
On May 27, 2020, the National Institutes of Health (NIH) announced it had found that molecules released into…
Vanderbilt University Medical Center professor Ege T Kavalali, Ph.D. received a Humboldt Research Award
On Dec. 31, 2019, Ege T. Kavalali, Ph.D., professor and acting chair of the Department of Pharmacology in…
Some 300 million people suffer from depression worldwide
On Mar. 31, 2017, more than 300 million people are now living with depression, which is the leading…
The UT Center for Depression Research and Clinical Care was established with a $5 million Hersh Foundation gift
On May 18, 2015, The Hersh Foundation annunced a $5 million lead gift to Southwestern Medical Foundation to…
Eli Lilly and Company launched new antidepressant Cymbalta
On Aug. 24, 2004, Eli Lilly and Company launched Cymbalta (duloxetine HC), a new treatment for major depression…
Eli Lilly and Company launched Symbyax in the U.S.
On Apr. 19, 2004, Eli Lilly and Company launched Symbyax in the U.S., the first and only Food…
Stanford researchers found Antidepressant helped alleviate compulsive shopping disorder
On Jun. 16, 2003, researchers at Stanford University Medical Center announced they found that a drug commonly prescribed…
Compulsive shopping research at Stanford seeks to treat mysterious disorder
On Dec. 16, 2002, researchers at Stanford University Medical Center announced they were continuing a multi-year clinical trial…